AlphaValue Corporate Services
This research has been commissioned and paid for by the company and is deemed to constitute an acceptable minor non-monetary benefit as defined in MiFID II


Bloomberg   ALCJ FP
Supergenerics  /  France  Web Site   |   Investors Relation
Things get going
Upside 149%
Price (€) 4.72
Market Cap (€M) 172
Perf. 1W: 7.40%
Perf. 1M: 5.48%
Perf. 3M: 16.7%
Perf Ytd: 43.1%
10 day relative perf. to stoxx600: 4.49%
20 day relative perf. to stoxx600: 1.61%
Target Change05/09/2018

On its way to reaching the market

Change in Target Price€ 17.8 vs 16.1+10.5%

Change in EPS2018 : € -0.94 vs -0.36ns
2019 : € -0.79 vs -0.06ns

We have fine-tuned our numbers in the back of the group’s latest comments as well as integrating the new NTE to be developed (Terbutaline) instead of Apomorphine which is now on stand-by. This said, short-term numbers have little meaning (other than the group’s cash-burn) since first sales should be booked in FY20.

Change in NAV€ 19.0 vs 18.2+4.78%

We have adjusted our numbers to take into account Terbutaline, the new therapeutic entity the group expects to develop alongside the six previous ones (already in our numbers). Some minor short-term changes have also impacted current net debt.

Change in DCF€ 24.9 vs 21.5+16.2%

Our DCF valuation goes up quite significantly after we integrated Terbutaline and fine-tuned our numbers (volumes and prices) for the other NTEs the group plans to market.


05 Sep 18 Target Change
On its way to reaching the market

17 May 18 Latest
Business update

22 Mar 18 Earnings/sales releases
On its way to reach the market…

03 Feb 18 Other news/comments
Orphan disease status for Zeneo® Midazolam i...

11 Dec 17 Other news/comments
Update on the company’s activities

25 Sep 17 Earnings/sales releases
H1 17: a new NTE in the pipeline...and further d...

06 Apr 17 Financing issue
The capital increase was successful